• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function.呼吸道合胞病毒F糖蛋白的中和表位:突变对融合功能的影响
J Virol. 1989 Jul;63(7):2941-50. doi: 10.1128/JVI.63.7.2941-2950.1989.
2
Antigenic and functional organization of human parainfluenza virus type 3 fusion glycoprotein.人副流感病毒3型融合糖蛋白的抗原性和功能组织
J Virol. 1989 Jan;63(1):375-82. doi: 10.1128/JVI.63.1.375-382.1989.
3
Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein.用呼吸道合胞病毒中和性人抗体Fab片段(Fab 19)筛选出的单克隆抗体抗性突变体在融合(F)糖蛋白上定义了一个独特的表位。
Virology. 1998 Dec 20;252(2):373-5. doi: 10.1006/viro.1998.9462.
4
Increased susceptibility of human respiratory syncytial virus to neutralization by anti-fusion protein antibodies on adaptation to replication in cell culture.人呼吸道合胞病毒在适应细胞培养复制后,对抗融合蛋白抗体中和作用的敏感性增加。
J Med Virol. 2007 Jun;79(6):829-37. doi: 10.1002/jmv.20892.
5
Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies.呼吸道合胞病毒融合蛋白上被鼠源和牛源单克隆抗体识别的保护性表位。
J Gen Virol. 1992 Sep;73 ( Pt 9):2217-23. doi: 10.1099/0022-1317-73-9-2217.
6
Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirus.人偏肺病毒融合蛋白上抗体中和表位的鉴定
J Gen Virol. 2008 Dec;89(Pt 12):3113-3118. doi: 10.1099/vir.0.2008/005199-0.
7
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.呼吸道合胞病毒融合纳米颗粒疫苗免疫应答针对多个中和表位,有助于预防野生型和帕利珠单抗耐药突变病毒的挑战。
Vaccine. 2018 Dec 18;36(52):8069-8078. doi: 10.1016/j.vaccine.2018.10.073. Epub 2018 Oct 30.
8
Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins.人类呼吸道合胞病毒F和G糖蛋白抗原结构存在显著差异。
J Virol. 1989 Feb;63(2):925-32. doi: 10.1128/JVI.63.2.925-932.1989.
9
Monoclonal antibodies to the large glycoproteins of respiratory syncytial virus: possible evidence for several functional antigenic sites.针对呼吸道合胞病毒大糖蛋白的单克隆抗体:多个功能性抗原位点的可能证据。
J Gen Virol. 1987 Aug;68 ( Pt 8):2161-7. doi: 10.1099/0022-1317-68-8-2161.
10
Identification of epitopes on respiratory syncytial virus proteins by competitive binding immunoassay.通过竞争性结合免疫测定法鉴定呼吸道合胞病毒蛋白上的表位
J Clin Microbiol. 1986 Mar;23(3):475-80. doi: 10.1128/jcm.23.3.475-480.1986.

引用本文的文献

1
A single amino acid mutation alters multiple neutralization epitopes in the respiratory syncytial virus fusion glycoprotein.单个氨基酸突变改变呼吸道合胞病毒融合糖蛋白中的多个中和表位。
Npj Viruses. 2025 Apr 22;3(1):33. doi: 10.1038/s44298-025-00119-8.
2
MERS-CoV spike vaccine-induced N-terminal domain-specific antibodies are more protective than receptor binding domain-specific antibodies.中东呼吸综合征冠状病毒刺突蛋白疫苗诱导产生的N端结构域特异性抗体比受体结合结构域特异性抗体更具保护性。
iScience. 2024 Dec 18;28(2):111632. doi: 10.1016/j.isci.2024.111632. eCollection 2025 Feb 21.
3
DS2 designer pre-fusion F vaccine induces strong and protective antibody response against RSV infection.DS2设计型预融合F疫苗可诱导针对呼吸道合胞病毒感染产生强烈且具有保护性的抗体反应。
NPJ Vaccines. 2024 Dec 31;9(1):258. doi: 10.1038/s41541-024-01059-9.
4
From setbacks to success: lessons from the journey of RSV vaccine development.从挫折到成功:呼吸道合胞病毒疫苗研发历程中的经验教训
Ther Adv Vaccines Immunother. 2024 Dec 19;12:25151355241308305. doi: 10.1177/25151355241308305. eCollection 2024.
5
Mutations in the F protein of the live-attenuated respiratory syncytial virus vaccine candidate ΔNS2/Δ1313/I1314L increase the stability of infectivity and content of prefusion F protein.活减呼吸道合胞病毒候选疫苗株 ΔNS2/Δ1313/I1314L 中 F 蛋白的突变增加了感染性的稳定性和融合前 F 蛋白的含量。
PLoS One. 2024 Apr 9;19(4):e0301773. doi: 10.1371/journal.pone.0301773. eCollection 2024.
6
All Eyes on the Prefusion-Stabilized F Construct, but Are We Missing the Potential of Alternative Targets for Respiratory Syncytial Virus Vaccine Design?所有目光都聚焦在预融合稳定的F结构上,但我们是否忽略了呼吸道合胞病毒疫苗设计中替代靶点的潜力?
Vaccines (Basel). 2024 Jan 18;12(1):97. doi: 10.3390/vaccines12010097.
7
Subtractive Immunization as a Method to Develop Respiratory Syncytial Virus (RSV)-Specific Monoclonal Antibodies.减式免疫法作为一种开发呼吸道合胞病毒(RSV)特异性单克隆抗体的方法。
Antibodies (Basel). 2023 Sep 26;12(4):62. doi: 10.3390/antib12040062.
8
Development of an anti- therapeutic monoclonal antibody WVDC-5244.抗治疗性单克隆抗体 WVDC-5244 的研发。
Front Cell Infect Microbiol. 2023 Apr 14;13:1117844. doi: 10.3389/fcimb.2023.1117844. eCollection 2023.
9
Identification of a DRB3*011:01-restricted CD4 T cell response against bovine respiratory syncytial virus fusion protein.鉴定针对牛呼吸道合胞体病毒融合蛋白的 DRB3*011:01 限制性 CD4 T 细胞反应。
Front Immunol. 2023 Feb 20;14:1040075. doi: 10.3389/fimmu.2023.1040075. eCollection 2023.
10
Evolutionary dynamics of respiratory syncytial virus in Buenos Aires: Viral diversity, migration, and subgroup replacement.布宜诺斯艾利斯呼吸道合胞病毒的进化动态:病毒多样性、迁移及亚组替代
Virus Evol. 2023 Jan 25;9(1):vead006. doi: 10.1093/ve/vead006. eCollection 2023.

本文引用的文献

1
RESPIRATORY SYNCYTIAL VIRUS: OBSERVATIONS ON ANTIGENIC HETEROGENEITY.呼吸道合胞病毒:关于抗原异质性的观察
Proc Soc Exp Biol Med. 1964 Jan;115:240-3. doi: 10.3181/00379727-115-28880.
2
Antigenic differences between two strains of respiratory syncytial virus.两种呼吸道合胞病毒株之间的抗原差异。
Proc Soc Exp Biol Med. 1963 Apr;112:958-64. doi: 10.3181/00379727-112-28221.
3
The stabilization and purification of respiratory syncytial virus using MgSO4.使用硫酸镁对呼吸道合胞病毒进行稳定化和纯化。
Virology. 1980 Oct 15;106(1):141-4. doi: 10.1016/0042-6822(80)90229-9.
4
Importance of antibodies to the fusion glycoprotein of paramyxoviruses in the prevention of spread of infection.副粘病毒融合糖蛋白抗体在预防感染传播中的重要性。
J Exp Med. 1980 Feb 1;151(2):275-88. doi: 10.1084/jem.151.2.275.
5
Classification of hybridomas to respiratory syncytial virus glycoproteins.针对呼吸道合胞病毒糖蛋白的杂交瘤分类
Proc Soc Exp Biol Med. 1982 Dec;171(3):266-71. doi: 10.3181/00379727-171-41509.
6
Monoclonal antibodies as functional probes of the HN glycoprotein of Newcastle disease virus: antigenic separation of the hemagglutinating and neuraminidase sites.单克隆抗体作为新城疫病毒HN糖蛋白的功能探针:血凝和神经氨酸酶位点的抗原分离
J Immunol. 1984 Oct;133(4):2215-9.
7
Use of the biotin-avidin system to study the specificity of antibodies against respiratory syncytial virus.利用生物素-抗生物素蛋白系统研究抗呼吸道合胞病毒抗体的特异性。
J Clin Microbiol. 1984 Jun;19(6):934-6. doi: 10.1128/jcm.19.6.934-936.1984.
8
Conversion of nonfusing mumps virus infections to fusing infections by selective proteolysis of the HN glycoprotein.通过对血凝素-神经氨酸酶(HN)糖蛋白进行选择性蛋白水解,将不融合的腮腺炎病毒感染转化为融合感染。
Virology. 1983 Dec;131(2):328-40. doi: 10.1016/0042-6822(83)90501-9.
9
Antigenic and structural variation in the major nucleocapsid protein of respiratory syncytial virus.呼吸道合胞病毒主要核衣壳蛋白的抗原性和结构变异
J Gen Virol. 1984 Oct;65 ( Pt 10):1749-57. doi: 10.1099/0022-1317-65-10-1749.
10
Monoclonal antibodies to human respiratory syncytial virus and their use in comparison of different virus isolates.抗人呼吸道合胞病毒单克隆抗体及其在不同病毒分离株比较中的应用。
J Gen Virol. 1984 May;65 ( Pt 5):963-71. doi: 10.1099/0022-1317-65-5-963.

呼吸道合胞病毒F糖蛋白的中和表位:突变对融合功能的影响

Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function.

作者信息

Beeler J A, van Wyke Coelingh K

机构信息

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.

出版信息

J Virol. 1989 Jul;63(7):2941-50. doi: 10.1128/JVI.63.7.2941-2950.1989.

DOI:10.1128/JVI.63.7.2941-2950.1989
PMID:2470922
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC250848/
Abstract

Eighteen neutralizing monoclonal antibodies (MAbs) specific for the fusion glycoprotein of the A2 strain of respiratory syncytial virus (RSV) were used to construct a detailed topological and operational map of epitopes involved in neutralization and fusion. Competitive binding assays identified three nonoverlapping antigenic sites (A, B, and C) and one bridge site (AB). Thirteen MAb-resistant mutants (MARMs) were selected, and the neutralization patterns of the MAbs with either MARMs or RSV clinical strains identified a minimum of 16 epitopes. MARMs selected with antibodies to six of the site A and AB epitopes displayed a small-plaque phenotype, which is consistent with an alteration in a biologically active region of the F molecule. Analysis of MARMs also indicated that these neutralization epitopes occupy topographically distinct but conformationally interdependent regions with unique biological and immunological properties. Antigenic variation in F epitopes was examined by using 23 clinical isolates (18 subgroup A and 5 subgroup B) in cross-neutralization assays with the 18 anti-F MAbs. This analysis identified constant, variable, and hypervariable regions on the molecule and indicated that antigenic variation in the neutralization epitopes of the RSV F glycoprotein is the result of a noncumulative genetic heterogeneity. Of the 16 eptiopes, 8 were conserved on all or all but 1 of 23 subgroup A or subgroup B clinical isolates.

摘要

使用18种针对呼吸道合胞病毒(RSV)A2株融合糖蛋白的中和单克隆抗体(MAb)构建了参与中和与融合的表位的详细拓扑和操作图谱。竞争性结合试验确定了三个不重叠的抗原位点(A、B和C)和一个桥接位点(AB)。选择了13个单克隆抗体抗性突变体(MARM),MAb与MARM或RSV临床毒株的中和模式确定了至少16个表位。用针对位点A和AB表位中六个表位的抗体选择的MARM表现出小噬斑表型,这与F分子生物活性区域的改变一致。对MARM的分析还表明,这些中和表位占据拓扑上不同但构象上相互依赖的区域,具有独特的生物学和免疫学特性。通过使用23株临床分离株(18株A亚组和5株B亚组)与18种抗F MAb进行交叉中和试验,检测了F表位的抗原变异。该分析确定了分子上的恒定、可变和高变区域,并表明RSV F糖蛋白中和表位的抗原变异是非累积性基因异质性的结果。在16个表位中,8个在23株A亚组或B亚组临床分离株的全部或除1株外的所有分离株上保守。